A new FDA fast-track program could undermine the agency’s role as a global drug safety authority.
Articles on Drug approval process
Displaying all articles
Here’s how a drug gets from an idea into patients’ hands – and why Australians sometimes wait longer to access a new drug than their American cousins.
The federal government’s proposed Agile Licensing drug approval regulations mean Canada will have less information about the risks of new medicines, and higher costs.
As the government’s oldest consumer protection agency, the FDA has long butted up against drugmakers, activists and politicians. But undermining its work could be harmful to patient health and safety.
The pharma industry claims lower prescription drug prices will mean less access to new medication for Canadians. It’s an old threat that pits profits against patients’ rights to affordable drugs.
The FDA receives almost half its funding from companies it regulates, such as drug and medical device makers. Is this something you should be concerned about?
Top contributors
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Professor of Law, Wake Forest University
-
Professor, School of Population and Public Health, University of British Columbia
-
Director of the Health Justice Institute at the Schulich School of Law, Dalhousie University
-
Christopher McCabe is a Friend of The Conversation.
Professor of Health Economics, Queen's University Belfast
-
Professor of Economics, University of Calgary
-
Associate Professor, School of Public Health, University of Alberta
-
Professor of Pharmaceutical Chemistry, Macquarie University